[The effect of bencyclan on shear induced platelet aggregation (author's transl)].
The platelet aggregation inhibiting effect of N-[3-(1-benzyl-cycloheptyloxy)-propyl]-N,N-dimethyl-amine (bencyclan, Fludilat) was studied by a new method for quantification of platelet aggregation in viscometric flow. In vitro-addition of bencyclan shows significant inhibition in a concentration of 1 mg/100 ml, total inhibition of platelet aggregation is found at a concentration of 5 mg/100 ml. Peroral application of bencyclan shows no significant effect on platelet aggregation. Intravenous application of bencyclan studied in three patients results in inhibition of platelet aggregation, however, no information about the duration of this platelet-inhibiting effect is yielded.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000284:Administration, Oral; D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D001537:Bencyclane / Q000008:administration & dosage / Q000494:pharmacology*; D003508:Cycloheptanes / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D009391:Nephelometry and Turbidimetry; D010974:Platelet Aggregation / Q000187:drug effects*; D012701:Serotonin / Q000494:pharmacology
D003508:Cycloheptanes; D012701:Serotonin; D000244:Adenosine Diphosphate; D001537:Bencyclane; D001241:Aspirin
Effekt von Bencyclan auf die scherungsinduzierte Plättchenaggregation